Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia

Pediatrics

Volumn 116, Issue 3, 2005, Pages 682-688

  Clauss, Sarah B ^a,e   Holmes, Kathryn W ^a   Hopkins, Paul ^b   Stein, Evan ^c   Cho, Meehyung ^d   Tate, Ann ^d   Johnson Levonas, Amy O ^d   Kwiterovich, Peter O ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Cardiovascular Genetics   (United States)

^c Metabolic and Atherosclerosis Research Center   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adolescents; Cholesterol; Lipids

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN; ASPARTATE AMINOTRANSFERASE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; MEVINOLIN; PLACEBO; PRASTERONE SULFATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ABDOMINAL PAIN; ADOLESCENCE; ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIETARY INTAKE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HETEROZYGOSITY; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MUSCLE FUNCTION; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; BLOOD; CHILD; DRUG EFFECT; GENETICS; GROWTH; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE 2; MULTICENTER STUDY;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CHILD; CHOLESTEROL, LDL; FEMALE; GROWTH; HETEROZYGOTE; HORMONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; LIPOPROTEINS; LOVASTATIN;

EID: 28244494371     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-2090     Document Type: Article

References (37)

1. McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 2000;20:1998-2004
2. McGill HC Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr. 2000;72(suppl):1307S-1315S
3. Strong JP, McGill HC Jr. The pediatric aspects of atherosclerosis. J Atheroscler Res. 1969;9:251-265
4. Restrepo C, Strong JP, McGill HC Jr. The natural history of aortic and coronary atherosclerosis in Columbia evaluated by necropsy examination. J Atheroscler Res. 1964;144:213-229
5. Strong JP, McGill HC Jr. The natural history of aortic atherosclerosis: relationship to race, sex and coronary lesions in New Orleans. Exp Mol Pathol. 1963;52(suppl):1-27
6. Strong JP, McGill HC Jr. The natural history of coronary atherosclerosis. Am J Pathol. 1962;40:37-49
7. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650-1656
8. Kwiterovich PO Jr, Levy RI, Fredrickson DS. Neonatal diagnosis of familial type-II hyperlipoproteinaemia. Lancet. 1973;1:118-121
9. Kwiterovich PO Jr, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974;53:1237-1249
10. Kwiterovich PO Jr, Barton BA, McMahon RP, et al. Effects of diet and sexual maturation on low-density lipoprotein cholesterol during puberty: the Dietary Intervention Study in Children (DISC). Circulation. 1997;96:2526-2533
11. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia. Lancet. 2004;363:369-370
12. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331-337
13. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89:495-501
14. American Academy of Pediatrics. National Cholesterol Education Program: report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89:525-584
15. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996;129:42-49
16. Liacouras CA, Coates PM, Gallagher PR, Cortner JA. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia. J Pediatr. 1993;122:477-482
17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622
18. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504
19. Havel RJ, Hunninghake DB, Illingworth DR, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med. 1987;107:609-615
20. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997;79:1475-1481
21. Bradford RH, Downton M, Chremos AN, et al. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med. 1993;118:850-855
22. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74:667-673
23. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, doubleblind, placebo-controlled trial with simvastatin. Circulation. 2002;106:2231-2237
24. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999;281:137-144
25. Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics. 1996;97:619-628
26. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996;39:867-871
27. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur J Pediatr. 2003;162:421-425
28. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469-2475
29. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143:74-80
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502
31. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 1975;19:65-76
32. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012
33. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II. JAMA. 1986;256:2829-2834
34. Shear CL, Franklin FA, Stinnett S, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation. 1992;85:1293-1303
35. Bairey Merz CN, Olson MB, Johnson BD, et al. Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women: the Women's Ischemia Syndrome Evaluation (WISE). Am J Med. 2002;113:723-727
36. Plotkin D, Miller S, Nakajima S, et al. Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, does not affect luteal function in premenopausal women. J Clin Endocrinol Metab. 2002;87:3155-3161
37. Ushiroyama T, Ikeda A, Ueki M, Sugimoto O. Efficacy and short-term effects of pravastatin, a potent inhibitor of HMG-Co A reductase, on hypercholesterolemia in climacteric women. J Med. 1994;25:319-331